Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot
法洛四联症心律失常和有氧能力受损的病理生理机制
基本信息
- 批准号:10661539
- 负责人:
- 金额:$ 56.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-01 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdultAerobicAgeAmericanArrhythmiaBiological MarkersBlood TestsCardiovascular systemCessation of lifeChronicClinicalClinical TrialsComplicationDataDeteriorationDevelopmentDiagnosticDiseaseEarly treatmentEchocardiographyEnrollmentEventExercise TestFutureGoalsHealth Care CostsHeartHeart AtriumHypertensionImageImpairmentInferior vena cava structureKnowledgeLaboratoriesLifeLife ExpectancyLinkMissionMorbidity - disease rateOperative Surgical ProceduresOutcomeOxygen ConsumptionPathogenesisPatientsPersonsPopulationPostoperative PeriodPreventionPrevention therapyProcessPublic HealthPulmonary Valve InsufficiencyRecurrenceReportingResearchRiskRisk FactorsSymptomsTechniquesTestingTetralogy of FallotTherapeutic InterventionTimeTroponinUncertaintyUnited States National Institutes of HealthVentricular Arrhythmiaarmburden of illnesscardiac magnetic resonance imagingcohortdisabilityeffective therapyevidence baseextracellularfollow-uphemodynamicsimprovedimproved outcomeindexinginnovationmortalitynovel therapeuticsprematurepressurepreventpro-brain natriuretic peptide (1-76)pulmonary valve replacementrepairedright ventricular failuresymptomatic improvementtreatment strategy
项目摘要
PROJECT SUMMARY/ABSTRACT
Right heart failure (RHF) is the leading cause of mortality in people with repaired tetralogy of Fallot (TOF), and
the sequence of events leading to this suboptimal outcome begins with pulmonary regurgitation (PR) and right
heart (RH) remodeling. Arrhythmias and impaired aerobic capacity are the most common presentations prior to
the onset of RHF, but performing pulmonary valve replacement (PVR) after the onset of these symptoms is not
associated with improved outcomes. Recent data show that elevated right atrial pressure (RA hypertension),
as estimated by echocardiographic assessment of inferior vena cava (IVC) size and collapsibility (IVC hemo-
dynamics), precedes the onset of arrhythmias and impaired aerobic capacity in TOF patients, and it is associ-
ated with accelerated RH remodeling, symptomatic deterioration and mortality in this population. However, the
mechanism linking RA hypertension, RH remodeling and symptomatic deterioration, and the extent to which
performing PVR prior to the onset of RA hypertension improves clinical outcomes are unknown. The long-term
goal is to prevent premature cardiovascular deaths in TOF patients by modifying the risk factors for mortality.
The overall objective is to delineate the pathophysiologic mechanism linking RA hypertension, RH remodeling
and onset of symptoms such as arrhythmias and impaired aerobic capacity, since symptomatic status is a risk
factor for mortality in the TOF population. Our central hypothesis is that RA hypertension leads to accelerated
RH remodeling and onset of symptoms (arrhythmias and impaired aerobic capacity), and that performing PVR
prior to onset of RA hypertension is associated with RH reverse remodeling and improvement of symptoms.
This hypothesis will be tested by pursuing two specific aims: (1) Determine the mechanism linking RA hyper-
tension (assessed by IVC hemodynamics), RH remodeling and onset of symptoms (arrhythmias and impaired
aerobic capacity) in TOF patients with moderate-severe PR; (2) Determine the extent to which performing PVR
prior to the onset of RA hypertension is associated with RH reverse remodeling (improvement of imaging and
biomarker indices of RH remodeling) and improvement of symptoms (less arrhythmias and improved aerobic
capacity). Under the first aim, 150 asymptomatic subjects (75 in each arm) will undergo imaging, laboratory
blood tests, exercise test, and patient reported quality of assessment at baseline, 12 months and 24 months.
Under the second aim, 120 subjects (60 in each arm) undergoing PVR for clinical indications will be enrolled to
undergo multi-domain assessments at baseline (prior to PVR), 12 months and 24 months similar to the first
aim. This proposal is innovative because it will delineate the mechanisms responsible for symptomatic deterio-
ration, and the impact of PVR on these mechanisms. The results will be significant because it will set the stage
for future clinical trials to test the survival benefits of PVR performed at different stages of disease pathogene-
sis, and development of novel therapies for the prevention and early treatment of RHF.
项目摘要/摘要
右心衰竭(RHF)是法洛四联症修复术(TOF)患者死亡的主要原因,
导致这一次优结局的事件序列始于肺返流(PR)和右
心脏(RH)重构。心律失常和有氧能力受损是最常见的表现
RHF的发病,但在这些症状出现后进行肺动脉瓣置换术(PVR)并不是
与改善结果相关。最近的数据显示,右房压力升高(RA高血压),
通过超声心动图评估下腔静脉(IVC)的大小和塌陷性(IVC血-
动力学),在TOF患者发生心律失常和有氧能力受损之前,它是相关联的
伴随着加速的RH重塑,症状恶化和死亡率。然而,
RA高血压、RH重塑和症状恶化之间的联系机制及其程度
在RA高血压发作之前进行PVR对临床结果的改善尚不清楚。长期的
目标是通过改变死亡率的危险因素来预防TOF患者的心血管过早死亡。
总体目标是阐明RA高血压、RH重塑的病理生理机制。
以及出现心律失常和有氧能力受损等症状,因为症状状态是一种风险
TOF人群中死亡的因素。我们的中心假设是RA高血压导致加速
RH重构和症状的出现(心律失常和有氧能力受损),以及进行PVR
RA发病前高血压与RH逆转重塑和症状改善有关。
这一假说将通过追求两个具体目标来检验:(1)确定RA过度兴奋的机制。
张力(通过下腔静脉血流动力学评估)、RH重构和症状的出现(心律失常和受损
中重度PR患者的有氧能力);(2)确定实施PVR的程度
在RA发病之前,高血压与RH反向重构有关(成像和
RH重塑的生物标志物指标)和症状的改善(心律失常减少和有氧能力改善
容量)。在第一个目标下,150名无症状受试者(每只手臂75名)将接受成像,实验室
在基线、12个月和24个月时,血液测试、运动测试和患者报告的质量评估。
在第二个目标下,120名因临床适应症而接受PVR的受试者(每组60人)将被登记为
在基线(在PVR之前)、12个月和24个月进行多领域评估,与第一次类似
瞄准。这项建议是创新的,因为它将勾勒出负责对症状进行威慑的机制。
定量,以及PVR对这些机制的影响。结果将是意义重大的,因为它将为
对于未来的临床试验,以测试在疾病病原体的不同阶段进行PVR的生存益处-
SIS,以及开发预防和早期治疗风湿性心衰的新疗法。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Prevalence and risk of progressive aortic aneurysm and dissection in adults with conotruncal anomalies.
患有圆锥干异常的成人进行性主动脉瘤和夹层的患病率和风险。
- DOI:10.1093/ehjci/jeab273
- 发表时间:2022
- 期刊:
- 影响因子:0
- 作者:Egbe,AlexanderC;Miranda,WilliamR;Bonnichsen,CrystalR;Jain,CCharles;Crestanello,JuanA;Francois,Christopher;Katta,RenukaR;Iftikhar,Momina;Goda,AhmedY;Andi,Kartik;Gandhi,Sangeetha;Connolly,HeidiM
- 通讯作者:Connolly,HeidiM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alexander Egbe其他文献
Alexander Egbe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alexander Egbe', 18)}}的其他基金
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
- 批准号:
10734120 - 财政年份:2023
- 资助金额:
$ 56.86万 - 项目类别:
Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot
法洛四联症心律失常和有氧能力受损的病理生理机制
- 批准号:
10458752 - 财政年份:2021
- 资助金额:
$ 56.86万 - 项目类别:
Mechanisms of Clinical and Hemodynamic Response to Pulmonary Vasodilator Therapy in Fontan physiology
Fontan 生理学中肺血管扩张剂治疗的临床和血流动力学反应机制
- 批准号:
10542724 - 财政年份:2021
- 资助金额:
$ 56.86万 - 项目类别:
Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot
法洛四联症心律失常和有氧能力受损的病理生理机制
- 批准号:
10268589 - 财政年份:2021
- 资助金额:
$ 56.86万 - 项目类别:
Ventricular and Pulmonary Vascular Reserve after the Fontan Operation
Fontan 手术后心室和肺血管储备
- 批准号:
10133126 - 财政年份:2018
- 资助金额:
$ 56.86万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 56.86万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 56.86万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 56.86万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 56.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 56.86万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 56.86万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 56.86万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 56.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 56.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 56.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)